ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Psychemedics Releases 2025 Workforce Insights Report

DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk.

The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industry, analyzing hundreds of thousands of samples collected in 2024 across a wide range of sectors, including transportation, manufacturing, healthcare, government, and more. The report reveals critical workforce trends and emerging threats employers must navigate in today’s rapidly changing drug climate.

Key findings from the 2025 report include:

  • Synthetic opioids on the rise: Fentanyl remains a top concern, with increasing detection of ultra-potent nitazenes, some up to 20x stronger than fentanyl.
  • Healthcare and manufacturing industries at highest risk: Positive drug test rates reached 14.7% and 14.6%, respectively.
  • Resurgence of cocaine and methamphetamine: Notable increases in stimulant use, particularly in high-pressure industries.
  • Legal marijuana and high THC potency: States with legalized recreational cannabis saw a 10% increase in workplace injuries among young workers.
  • Hair testing remains the most reliable method, offering a 90-day detection window and unmatched resistance to evasion, making it the gold standard for long-term drug detection.

“As the drug landscape evolves, with new synthetic substances, rising marijuana potency, and shifting laws, employers are under growing pressure to maintain safe, compliant, and productive workplaces,” said Brian Hullinger, President and CEO of Psychemedics.

The 2025 report emphasizes the need for comprehensive drug testing strategies that extend beyond detection to include education, prevention, and support. By offering deep insight into five-year trends and sector-specific risks, Psychemedics equips employers with the tools to adapt policies, mitigate liability, and make informed decisions.

The full 2025 Workforce Insights Report is available at: https://www.psychemedics.com/whitepaper/

For more information about Psychemedics Corporation and its innovative hair testing solutions, visit https://www.psychemedics.com.

About Psychemedics 

Psychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.

Investor Relations:
Phone: 978-206-8220
Email: InvestorRelations@psychemedics.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.